This company has been marked as potentially delisted and may not be actively trading. Apricus Biosciences (APRI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock APRI vs. SCPS, EVLO, CMRA, ARDS, STAB, EFTR, MTEM, AMPE, PXMD, and ONCSQShould you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), Molecular Templates (MTEM), Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), and OncoSec Medical (ONCSQ). These companies are all part of the "medical" sector. Apricus Biosciences vs. Scopus BioPharma Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Molecular Templates Ampio Pharmaceuticals PaxMedica OncoSec Medical Scopus BioPharma (NASDAQ:SCPS) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is SCPS or APRI more profitable? Scopus BioPharma's return on equity of 0.00% beat Apricus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Apricus Biosciences N/A -216.45%-153.13% Which has higher earnings & valuation, SCPS or APRI? Apricus Biosciences has higher revenue and earnings than Scopus BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AApricus Biosciences$5.76M0.00$320K-$0.990.00 Do insiders & institutionals hold more shares of SCPS or APRI? 19.9% of Apricus Biosciences shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 2.3% of Apricus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to SCPS or APRI? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Apricus Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Apricus Biosciences Neutral Does the MarketBeat Community favor SCPS or APRI? Apricus Biosciences received 228 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 69.91% of users gave Apricus Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesApricus BiosciencesOutperform Votes23069.91% Underperform Votes9930.09% Which has more risk and volatility, SCPS or APRI? Scopus BioPharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. SummaryApricus Biosciences beats Scopus BioPharma on 5 of the 9 factors compared between the two stocks. Remove Ads Get Apricus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRI vs. The Competition Export to ExcelMetricApricus BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$14,000.00$6.78B$5.58B$7.91BDividend YieldN/A2.81%5.35%4.04%P/E Ratio0.007.1823.6218.80Price / Sales0.00205.88369.2688.94Price / CashN/A65.6738.1634.64Price / Book0.006.126.704.17Net Income$320,000.00$142.11M$3.20B$247.10M Apricus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APRIApricus BiosciencesN/A$0.00flatN/A-99.9%$14,000.00$5.76M0.00N/ASCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-99.0%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+3,999,900.0%-100.0%$3,000.00$3.55M0.0010MTEMMolecular Templates1.0258 of 5 stars$0.00+300.0%N/A-100.0%$3,000.00$23.48M0.00260Gap UpAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoveragePXMDPaxMedicaN/A$0.00flatN/A-100.0%$2,000.00N/A0.002ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040 Remove Ads Related Companies and Tools Related Companies SCPS Competitors EVLO Competitors CMRA Competitors ARDS Competitors STAB Competitors EFTR Competitors MTEM Competitors AMPE Competitors PXMD Competitors ONCSQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRI) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APRI Stock Free APRI Stock Alerts